Key Drivers
- Positive EBITDA
- Strong Free Cash Flow
- Elevated Leverage
AIAI Summary
IRTC's upside depends on proving that ZEUS automation and VitalConnect can convert 20%+ growth into sustained >70% gross margins and durable free cash flow, but investors should wait for margin performance to align with the weaker 12%–14% EBITDA outlook amid reimbursement, regulatory, integration, and leverage risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Positive EBITDA
- •Strong Free Cash Flow
- •Elevated Leverage
IRTC shows improving profitability and strong cash generation, but high leverage, persistent deficits, and a demanding valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Persistent downtrend
- •Oversold momentum
- •Critical support
IRTC remains in a last-month downtrend below its average; watch $109–$110 support for a bounce, but a break lower favors continued weakness.
Accelerated decline from $123.07 to $109.33
Sentiment & News
Key News Insights:
- •Margin Expansion
- •ZEUS Efficiency
- •Institutional Buying
iRhythm's strong growth, margin expansion, ZEUS-driven efficiency potential, raised guidance, and increased institutional buying support a positive outlook despite reimbursement and regulatory risks.
The developments are likely supportive for iRhythm's valuation momentum, though regulatory and reimbursement uncertainty remains a key watchpoint
Similar Companies in Healthcare
Other companies in the same sector with AI ratings